IMV Stock Forecast, Price & News

-0.08 (-2.76 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $2.82
50-Day Range
MA: $3.29
52-Week Range
Now: $2.82
Volume116,009 shs
Average Volume277,310 shs
Market Capitalization$190.71 million
P/E RatioN/A
Dividend YieldN/A
IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IMV logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMV
Phone902 492 1819
Year FoundedN/A



Sales & Book Value

Annual Sales$430,000.00
Book Value$0.10 per share


Net Income$-20,620,000.00
Net Margins-9,661.54%


Market Cap$190.71 million
Next Earnings Date5/21/2021 (Estimated)


Is IMV (TSE:IMV) A Risky Investment? - Yahoo Finance
April 8, 2021 |
Is IMV (TSE:IMV) A Risky Investment?
April 8, 2021 |
IMV Inc. (NASDAQ:IMV) Short Interest Update
April 2, 2021 |
-$0.12 EPS Expected for IMV Inc. (NASDAQ:IMV) This Quarter
April 2, 2021 |
IMV (NASDAQ:IMV) Rating Reiterated by Leede Jones Gab
March 23, 2021 |
Stocks Stumble at Outset -
March 18, 2021 |
See More Headlines


Overall MarketRank

0.78 out of 5 stars

Medical Sector

1201st out of 2,016 stocks

Pharmaceutical Preparations Industry

534th out of 771 stocks

Analyst Opinion: 3.3Community Rank: 0.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.08 (-2.76 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

IMV (NASDAQ:IMV) Frequently Asked Questions

Is IMV a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMV stock.
View analyst ratings for IMV
or view top-rated stocks.

What stocks does MarketBeat like better than IMV?

Wall Street analysts have given IMV a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IMV wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IMV?

IMV saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 839,200 shares, an increase of 31.9% from the February 28th total of 636,400 shares. Based on an average trading volume of 324,100 shares, the short-interest ratio is currently 2.6 days. Currently, 1.4% of the shares of the company are sold short.
View IMV's Short Interest

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for IMV

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) released its earnings results on Tuesday, March, 16th. The company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.01. IMV had a negative net margin of 9,661.54% and a negative trailing twelve-month return on equity of 180.04%.
View IMV's earnings history

How has IMV's stock price been impacted by Coronavirus?

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMV shares have increased by 18.5% and is now trading at $2.82.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IMV?

7 Wall Street analysts have issued 12-month target prices for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's stock price to reach $8.54 in the next year. This suggests a possible upside of 202.9% from the stock's current price.
View analysts' price targets for IMV
or view top-rated stocks among Wall Street analysts.

Who are IMV's key executives?

IMV's management team includes the following people:
  • Mr. Frederic Ors M.B.A., B.Sc., M.A., CEO & Director (Age 47)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 56)
  • Ms. Joanne Schindler, Chief Medical Officer
  • Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations
  • Ms. Annie Tanguay B.Sc., Sr. VP of Quality & Compliance
  • Delphine Davan, Director of Communications
  • Mr. Andrew Hall M.Sc., Chief Bus. Officer
  • Dr. Marianne Stanford, VP of R&D

Who are some of IMV's key competitors?

What is IMV's stock symbol?

IMV trades on the NASDAQ under the ticker symbol "IMV."

How do I buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $2.82.

How much money does IMV make?

IMV has a market capitalization of $190.71 million and generates $430,000.00 in revenue each year. The company earns $-20,620,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does IMV have?

IMV employs 62 workers across the globe.

What is IMV's official website?

The official website for IMV is

Where are IMV's headquarters?

IMV is headquartered at 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4.

How can I contact IMV?

IMV's mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The company can be reached via phone at 902 492 1819 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.